HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in light of potential economic sensitivity to the adoption curve for weight loss drugs.
In a turbulent year for financial markets, US equities and real estate investment trusts are still bearing the brunt of the selling so far in 2025, based on a set of ETFs.
The $150 billion investment will include more than $30 billion in research and development to advance and continue IBM's American manufacturing of mainframe and quantum computers.
For the full year, Revvity raised its revenue guidance to a range of $2.83 billion to $2.87 billion to reflect recent changes in foreign currency exchange rates.
Bernstein stated that after high Federal Aviation Administration (FAA) scrutiny, Boeing Commercial Airplanes "should be on a much firmer path than in 2023.”
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.
The company now expects the health benefits ratio for the full year to be in the range of 88.9% to 89.5%, up from its previous guidance of 88.4% to 89%.
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.
The company reportedly said the layoffs were meant to help Oculus Studios work more efficiently on future mixed-reality experiences for its growing audience.
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE subcutaneous delivery technology.
